Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD6008 in Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
NCT06905197Phase 1Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- May 2025
- Primary completion
- Sep 2027
- Countries
- 2
01
Overview
Phase 1, open-label trial of DZD6008 in non-small cell lung cancer (NSCLC) (13 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability at 1 year and Anti-tumor activity at 1 year. Started May 2025; status: recruiting.
02
Drugs
DZD6008
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06905197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06905197.